India: Life Sciences, Biotechnology & Nanotechnology

India has redrawn how it examines biotech patents for the first time since 2013. If you own a portfolio in pharma, biologics, biosimilars or diagnostics, the draft changes what will get granted in India — and what won’t.

The Delhi High Court (Justice Jyoti Singh) allowed a cancellation petition under Section 57 and struck DAPLOGIN (Class 5) from the Register, finding it deceptively similar to Dr. Reddy’s earlier coined mark DAPLO for a diabetes drug with the same active ingredient, dapagliflozin.

India's life sciences regulatory landscape in July 2026 saw major developments across pharmaceuticals, medical devices, and healthcare regulation. Key changes included the draft National Pharmacy Commission Bill proposing to replace the 80-year-old Pharmacy Act, CDSCO's final guidance on Medical Device Software establishing clear market access pathways, and stricter controls on high-alcohol oral formulations under Schedule H1.

India's life sciences and healthcare sector saw significant regulatory shifts in April 2026, including proposed decriminalization of minor violations, new medical device testing fees, and streamlined foreign training requirements for healthcare professionals. Courts also delivered key rulings on pharmaceutical trademark disputes, reinforcing stricter standards for drug name similarity.

India's healthcare and pharmaceutical sectors are undergoing significant regulatory transformation through new frameworks for AI adoption, enhanced surveillance of drug supply chains, and streamlined approval processes.

On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to acquire all outstanding shares of Organon...

Welcome to the September 2025 edition of our Life Sciences and Healthcare Newsletter, where we delve into the latest developments shaping the industry.

Agriculture has always been the backbone of human civilization and safeguarding plant genetic resources has become a crucial endeavor in the 21st century.

In the past couple of months, the healthcare and pharmaceutical sectors have undergone a series of structural reforms and policy adjustments, highlighting a clear focus on enhancing patient-centricity, standardising quality benchmarks, and streamlining regulatory compliance.